C2i Genomics

C2i Genomics develops liquid biopsy technology that uses whole-genome sequencing and AI to detect residual cancer and monitor treatment response in patients. The company serves clinicians, researchers, and pharmaceutical companies by providing longitudinal cancer monitoring through blood samples.